Vasigrobart

瓦西古拜单抗

Report date: 2026/04/30 20:00:20

Base Information

Drug NameVasigrobart
Drug Alias NameREGN13335REGN-13335
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPlatelet-derived growth factor subunit B antagonists
TargetsPlatelet-derived growth factor subunit B
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A